|
1. Siegfried reports higher profits, sales with growth in all
businesses
MOSCOW (MRC) -- Siegfried says its core net profit for 2020
increased 10.4%, to 72.2 million Swiss francs (USD79.6 million) on sales up
1.4%, to SFr845.1 million, said Chemweek. Core EBITDA also grew by 6.2%, to
SFr149.4 million. The positive performance was driven by growth in the company’s
two businesses with sales in drug substances going up 1.4%, to SFr647.8 million,
and drug products’ sales increasing 1.2%, to SFr197.2 million. Fourth-quarter
figures have not been disclosed. Siegfried expects “a significant jump” in sales
in 2021, to well above SFr1 billion, driven by robust organic growth in all
business areas, the contributions of the two former Novartis sites, and the
additional business from a cooperation and supply agreement with BioNTech for
the Pfizer/BioNTech COVID-19 vaccine.
http://www.mrcplast.com/news-news_open-384196.html
|
